

HTRF® Europium cryptate donor / Red acceptor readout Setup recommendations for ARTEMIS 101

Two sequential measurements will be carried out: at 620 nm for the cryptate emission, and at 665 nm for the specific signal emitted by the acceptor (XL665 or d2). The ratio* of the fluorescence intensities 665/620 (acceptor/donor) enables the calculation of Delta F (%) which represents the relative energy transfer rate for each sample.

Artemis readers must be appropriately configured for HTRF® readout by setting up the measurement conditions in the "test protocol setting" function of the software piloting the reader. These parameters should be specifically entered as defined in the table below. No special upgrade is required for HTRF® readout, as it is a dedicated instrument:

Setup	
Delay time	100 µs
Integration time	100 µs
Number of flashes	50



**The fluorescence ratio is a correction method developed by Cisbio Bioassays with an application limited to the use of HTRF® reagents and technology, and for which Cisbio Bioassays has granted a licence to FURUNO. The method is covered by the US patent 5,527,684 and its foreign equivalents.*

HTRF® Terbium cryptate donor / Red acceptor readout Setup recommendations for ARTEMIS 101

Two sequential measurements will be carried out: at 620 nm for the cryptate emission, and at 665 nm for the specific signal emitted by the acceptor (XL665 or d2). The ratio* of the fluorescence intensities 665/620 (acceptor/donor) enables the calculation of Delta F (%) which represents the relative energy transfer rate for each sample.

Artemis readers must be appropriately configured for HTRF® readout by setting up the measurement conditions in the "test protocol setting" function of the software piloting the reader. These parameters should be specifically entered as defined in the table below. No special upgrade is required for HTRF® readout, as it is a dedicated instrument:

Setup	
Delay time	100 µs
Integration time	100 µs
Number of flashes	50



*The fluorescence ratio is a correction method developed by Cisbio Bioassays with an application limited to the use of HTRF® reagents and technology, and for which Cisbio Bioassays has granted a licence to FURUNO. The method is covered by the US patent 5,527,684 and its foreign equivalents.